These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27840335)

  • 1. Imprecision: Limitations to Interpretation of a Large Randomized Clinical Trial.
    FitzGerald GA
    Circulation; 2017 Jan; 135(2):113-115. PubMed ID: 27840335
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapy: Cardiovascular safety of celecoxib, naproxen and ibuprofen.
    Nurmohamed MT
    Nat Rev Rheumatol; 2017 Mar; 13(3):136-138. PubMed ID: 28127041
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
    Nissen SE; Yeomans ND; Solomon DH; Lüscher TF; Libby P; Husni ME; Graham DY; Borer JS; Wisniewski LM; Wolski KE; Wang Q; Menon V; Ruschitzka F; Gaffney M; Beckerman B; Berger MF; Bao W; Lincoff AM;
    N Engl J Med; 2016 Dec; 375(26):2519-29. PubMed ID: 27959716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective].
    De Lossada A; Oteo-Álvaro Á; Giménez S; Oyagüez I; Rejas J
    Semergen; 2016; 42(4):235-43. PubMed ID: 26006311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
    Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Celecoxib safety revisited.
    Med Lett Drugs Ther; 2016 Dec; 58(1510):159. PubMed ID: 27960193
    [No Abstract]   [Full Text] [Related]  

  • 7. The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial.
    Solomon DH; Husni ME; Libby PA; Yeomans ND; Lincoff AM; Lϋscher TF; Menon V; Brennan DM; Wisniewski LM; Nissen SE; Borer JS
    Am J Med; 2017 Dec; 130(12):1415-1422.e4. PubMed ID: 28756267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Coronary risks with NSAID and coxibs. The end of hysteria].
    Einecke D
    MMW Fortschr Med; 2006 Nov; 148(48):10, 12. PubMed ID: 17615760
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
    De Vecchis R; Baldi C; Di Biase G; Ariano C; Cioppa C; Giasi A; Valente L; Cantatrione S
    Minerva Cardioangiol; 2014 Dec; 62(6):437-48. PubMed ID: 25029569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP; Curtis SP; FitzGerald GA; Krum H; Kaur A; Bolognese JA; Reicin AS; Bombardier C; Weinblatt ME; van der Heijde D; Erdmann E; Laine L;
    Lancet; 2006 Nov; 368(9549):1771-81. PubMed ID: 17113426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Celecoxib for osteoarthritis.
    Rowan-Robinson K
    Br J Community Nurs; 2019 Oct; 24(10):501-502. PubMed ID: 31604050
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
    Farkouh ME; Greenberg JD; Jeger RV; Ramanathan K; Verheugt FW; Chesebro JH; Kirshner H; Hochman JS; Lay CL; Ruland S; Mellein B; Matchaba PT; Fuster V; Abramson SB
    Ann Rheum Dis; 2007 Jun; 66(6):764-70. PubMed ID: 17412741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Not Available].
    Steurer J
    Praxis (Bern 1994); 2018 Apr; 107(8):469-470. PubMed ID: 29642790
    [No Abstract]   [Full Text] [Related]  

  • 14. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What price pain relief?
    Hochman JS; Shah NR
    Circulation; 2006 Jun; 113(25):2868-70. PubMed ID: 16785335
    [No Abstract]   [Full Text] [Related]  

  • 16. [3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]].
    Krüger K
    MMW Fortschr Med; 2006 Nov; 148(48):12. PubMed ID: 17615761
    [No Abstract]   [Full Text] [Related]  

  • 17. Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now.
    Patrono C; Baigent C
    Clin Pharmacol Ther; 2017 Aug; 102(2):238-245. PubMed ID: 28378879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
    Bensen WG; Fiechtner JJ; McMillen JI; Zhao WW; Yu SS; Woods EM; Hubbard RC; Isakson PC; Verburg KM; Geis GS
    Mayo Clin Proc; 1999 Nov; 74(11):1095-105. PubMed ID: 10560596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analgesics, NSAIDS, and coxibs in rheumatic pain].
    Di Matteo L
    Reumatismo; 2006; 58 Spec No.1():84-9. PubMed ID: 23631071
    [No Abstract]   [Full Text] [Related]  

  • 20. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.
    Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.